An observational study in Asthma and COPD, sponsored by Orion Corporation, Orion Pharma. Terminated at 1 site in Norway. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-09-23.
Sponsored by Orion Corporation, Orion Pharma · Observational
This is a retrospective, multicentre, non-interventional, observational study in patients with asthma and/or COPD who are treated with budesonide-formoterol.
In July 2018 Norwegian authorities decided to allow switch at pharmacy for dry powder inhalers (DPIs) containing budesonide-formoterol. Pharmacists are instructed to switch patients to the inhaler with the lowest price. The pharmacist will train the patient on how to use the new inhaler. All patients whose eligible inhaler switch occurred between 1st July 2018 and 1st March 2019 will be eligible for the study.
3,920 studies on the registry are indexed under Asthma; 506 are open to participants now.
This study's enrollment of 29 is below the median of 150 across 970 observational studies indexed under Asthma.
Browse Asthma studies →Orion Corporation, Orion Pharma is the lead sponsor of 100 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with asthma and/or COPD treated with budesonide-formoterol DPI
Exclusion Criteria:
Dry powder inhaler
Disease control
The number of asthma and/or COPD exacerbations during the 12 months pre-switch and the 12 months post-switch.
Time frame: 24 months
Budesonide-formoterol dose
The change in the treatment dose of budesonide-formoterol at the time of the eligible switch and at the end of the post-switch period (e.g. 12 months post-switch).
Time frame: 24 months
Training at pharmacy
The correlation between inhaler training given at pharmacy and exacerbations.
Time frame: 24 months
Healthcare utilisation
The number of asthma and/or COPD related hospitalisations, emergency room visits and visits to physicians 12 months pre-switch and 12 months post-switch.
Time frame: 24 months
Inhaler switch
The number of re-switches after the first 'eligible' switch and the reasons for that switch.
Time frame: 24 months
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Orion Corporation, Orion Pharma